CompletedNot Applicable

Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis

Burma30 participantsStarted 2020-10-01

Plain-language summary

To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.

Who can participate

Age range14 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with HIV-associated cryptococcal meningitis, admitted to inpatient department of SHW, SHM, SHT, YGH, NOGTH and IGH during the study period
✓. Patients of both sexes
✓. Age above 14 years
✓. Patients or caregivers who will give informed consent to participate in this study

What they're measuring

Clinical effectiveness

Timeframe: 14 days (day1 to day 14)

Clinical safety

Timeframe: 14 days (day1 to day 14)

Trial details

NCT IDNCT04532463

SponsorUniversity of Pharmacy, Yangon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03-30

View on ClinicalTrials.gov More Cryptococcal Meningitis trials